Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
Golimumab
Janssen Biologics B.V.
L04AB06
golimumab
Immunosuppressants
Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid
Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Revision: 48
Authorised
2009-10-01
129 B. PACKAGE LEAFLET 130 PACKAGE LEAFLET: INFORMATION FOR THE USER SIMPONI 45 MG/0.45 ML SOLUTION FOR INJECTION IN PRE-FILLED PEN For paediatric patients below 40 kg golimumab READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. Your doctor will also give you a Patient Reminder Card, which contains important safety information you need to be aware of before and during your treatment with Simponi. WHAT IS IN THIS LEAFLET 1. What Simponi is and what it is used for 2. What you need to know before you use Simponi 3. How to use Simponi 4. Possible side effects 5. How to store Simponi 6. Contents of the pack and other information 1. WHAT SIMPONI IS AND WHAT IT IS USED FOR Simponi contains the active substance called golimumab. Simponi belongs to a group of medicines called ‘TNF blockers’. It is used IN CHILDREN 2 years of age and older for the treatment of polyarticular juvenile idiopathic arthritis. Simponi works by blocking the action of a protein called ‘tumour necrosis factor alpha’ (TNF-α). This protein is involved in inflammatory processes of the body, and blocking it can reduce the inflammation in your body. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS Polyarticular juvenile idiopathic arthritis is an inflammatory disease that causes joint pain and swelling in children. If you have polyarticular juvenile idiopathic arthritis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Simponi in combination with methotrexate to treat the disease. 2. WHAT YO Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Simponi 45 mg/0.45 mL solution for injection in pre-filled pen. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One pre-filled pen contains 45 mg golimumab* in 0.45 mL. 1 mL solution contains 100 mg golimumab. Each pre-filled pen can deliver 0.1 mL to 0.45 mL (corresponding to 10 mg to 45 mg golimumab) in increments of 0.05 mL. * Human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology. Excipient with known effect Each pre-filled pen contains 18.45 mg sorbitol (E420) per 45 mg dose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection in pre-filled pen (injection), VarioJect The solution is clear to slightly opalescent, colourless to light yellow. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Juvenile idiopathic arthritis _Polyarticular juvenile idiopathic arthritis (pJIA)_ Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of conditions for which Simponi is indicated. Patients treated with Simponi should be given the Patient Reminder Card which is included in the pack. Posology The 45 mg/0.45 mL pre-filled pen is for paediatric patients. Each pre-filled pen is for single use in a single patient, and should be discarded immediately after use. Paediatric population Juvenile idiopathic arthritis _Polyarticular juvenile idiopathic arthritis in children with body weight less than 40 kg_ The recommended dose of Simponi for children with a body weight less than 40 kg with polyarticular juvenile idiopathic arthritis is 30 mg/m 2 body surface area up to maximum single dose of 40 mg 3 administered once a month, on the same date ea Læs hele dokumentet